We investigated the potential protective effect of rutinum (RUT) against pirarubicin- (THP-) induced cardiotoxicity. THP was used to induce toxicity in rat H9c2 cardiomyoblasts. Positive control cells were pretreated with a cardioprotective agent dexrazoxane (DZR) prior to treatment with THP. Some of the cells were preincubated with RUT and a p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, both individually and in combination, prior to THP exposure. At a dose range of 30-70 M, RUT significantly prevented THP-induced reduction in cell viability; the best cardioprotective effect was observed at a dose of 50 M. Administration of RUT and SB203580, both individually as well as in combination, suppressed the elevation of intracellular ROS, inhibited cell apoptosis, and reversed the THP-induced upregulation of TGF-1, p-p38 MAPK, cleaved Caspase-9, Caspase-7, and Caspase-3. A synergistic effect was observed on coadministration of RUT and SB203580. RUT protected against THP-induced cardiotoxicity by inhibition of ROS generation and suppression of cell apoptosis. The cardioprotective effect of RUT appears to be associated with the modulation of the TGF-1-p38 MAPK signaling pathway.
Can J Physiol Pharmacol. 2016 Sep;94(9):996-1006
[PMID:
27376621]
Rev Port Cardiol. 2016 Jun;35(6):359-71
[PMID:
27255173]
Future Cardiol. 2012 Jul;8(4):647-70
[PMID:
22871201]
Arch Med Res. 2013 Jul;44(5):346-51
[PMID:
23867787]
Curr Med Chem. 2016;23 (9):860-73
[PMID:
26898570]
J Natl Cancer Inst. 2015 Nov 23;108(4):null
[PMID:
26598513]
Acta Histochem. 2015 Oct;117(8):803-10
[PMID:
26251197]
Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1916-25
[PMID:
26828775]
Mol Med Rep. 2016 Jul;14 (1):551-9
[PMID:
27177246]
Curr Eye Res. 2016 Jul;41(7):933-42
[PMID:
26576853]
Mol Biol Cell. 2003 Feb;14 (2):529-44
[PMID:
12589052]
Exp Ther Med. 2016 Jun;11(6):2407-2412
[PMID:
27284328]
Methods Enzymol. 2004;378:340-61
[PMID:
15038979]
EXCLI J. 2015 Jan 09;14:59-63
[PMID:
26535031]
Yonsei Med J. 2016 Mar;57(2):373-81
[PMID:
26847289]
Zhong Yao Cai. 2014 Apr;37(4):640-4
[PMID:
25345141]
J Virol. 2015 Dec 04;90(4):1729-40
[PMID:
26637457]
Arch Med Sci. 2016 Apr 1;12(2):428-35
[PMID:
27186191]
Int Immunopharmacol. 2016 Mar;32:1-7
[PMID:
26774212]
Chin J Integr Med. 2016 Mar 17;:null
[PMID:
27048408]
Chem Biol Interact. 2015 Apr 25;231:98-107
[PMID:
25753322]
Biomaterials. 2011 Jul;32(21):4857-66
[PMID:
21486680]
Oxid Med Cell Longev. 2015;2015:795602
[PMID:
26491536]
J Endocrinol Invest. 2014 Sep;37(9):783-8
[PMID:
24879037]
J Mol Cell Cardiol. 2005 Jan;38(1):47-62
[PMID:
15623421]
Neurochem Res. 2014 Apr;39(4):707-18
[PMID:
24549762]
Arch Biochem Biophys. 2014 Oct 1;559:38-45
[PMID:
24875145]
Environ Toxicol. 2012 Aug;27(8):480-4
[PMID:
21254320]
Int J Mol Sci. 2013 Jun 04;14(6):11830-41
[PMID:
23736691]
J Appl Toxicol. 2016 Apr;36(4):609-17
[PMID:
26472149]
Arch Toxicol. 2016 Sep;90(9):2063-76
[PMID:
27342245]
Clin Sci (Lond). 2008 Oct;115(7):203-18
[PMID:
18752467]
